Journal of Clinical Oncology
Articles in this Issue
Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma.
2013 Background: Isocitrate dehydrogenase (IDH) 1 or IDH2 mutations or co-mutations have been associated with various tumors, including glioma. HMPL-306 (...
Second malignant neoplasm risk after mediastinal radiotherapy for pediatric Hodgkin lymphoma on Children’s Oncology Group AHOD1331.
10019 Background: The reported incidence of second malignant neoplasms (SMN) in long-term survivors of Hodgkin lymphoma (HL) is derived from patients trea...
Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): Results from the Beamion LUNG-1 trial.
8620 Background: Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFR, thereby limiting associated t...
Concurrent acute myeloid leukemia and chronic lymphocytic leukemia: A review and clinical insights.
e18513 Background: Chronic lymphocytic leukemia (CLL) is the most common indolent lymphoproliferative neoplasm in older adults, frequently associated with...
Assessing the predictive role of tumor sidedness in <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials.
3538 Background: Chemotherapy (chemo) + an anti-EGFR and chemo + bev are currently regarded as preferred upfront options for left- and right-sided pMMR...
Regional and demographic disparities in multiple myeloma and cardiovascular disease mortality (1999–2020).
e13537 Background: Multiple Myeloma (MM) and cardiovascular disease (CVD) significantly impact U.S. mortality. This study examines regional and demographi...
Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.
4027 Background: Studies have shown overall survival improvements with nCRT + surgery vs surgery alone in locally advanced ESCC. However, preoperative CRT...
Predictors and patterns of recurrence, and the impact of adjuvant radiation in early stage (pT1-2, N0) oral cavity squamous cell carcinoma: A matched pair analysis.
e18076 Background: Early stage constitutes around 40% of all Oral cavity Squamous Cell Carcinoma (OSCC). While the role Post Operative Radiation Therapy (...
Effect of erythrocyte-antibody conjugates on cancers resistant to checkpoint blockade immunotherapy: A phase I trial.
2506 Background: Despite the clinical success of immune checkpoint blockade therapy, the majority of patients do not benefit due to inadequate efficacy as...
Performance of <sup>177</sup> Lu-PSMA-I&T for RLT in mCRPC: First prospective data of a multicenter Swiss registry study.
e17063 Background: 177 Lu-PSMA-617 has been established as a radioligand therapy (RLT) for patients with metastatic castration-resistant prost...
Trends in early-onset gastrointestinal cancers: A comprehensive analysis of US cancer statistics (2001–2021).
11182 Background: Early-onset colorectal cancer (eoCRC) has become a well-recognized phenomenon in recent years. This study aims to explore trends in othe...
Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.
2572 Background: SAR445877 is a fusion protein of an PD-1 antibody combined with a detuned IL-15, designed to selectively expand and activate CD8+ T and N...
Siglec15 as a potential therapeutic target for the treatment of fibrosarcoma.
e23552 Background: Traditional therapeutic approaches, including surgery, radiotherapy, and chemotherapy, have limited effectiveness in controlling the pr...
Unveiling the genetic role of skin-gut microbial axis in pan-cancer development.
e22503 Background: The skin and gut are critical, microbe-rich barriers whose dynamic interplay modulates immune homeostasis and disease susceptibility. A...
Clinical outcomes of hemophagocytic lymphohistiocytosis in patients with HIV-related lymphomas: A multicentre observational study.
7071 Background: Secondary Hemophagocytic Lymphohistiocytosis (HLH) is a rare and potentially fatal inflammatory disorder triggered by infections, maligna...
Secondary primary malignancies, cancer-specific survival, and disparities in enucleation: An overview of ocular melanoma from Surveillance, Epidemiology, and End Results (SEER) data (2000-2021).
e23354 Background: Ocular melanoma (OM) is a rare, aggressive malignancy, accounting for most primary intraocular tumors in adults over 50 years of age. S...
Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).
12007 Background: CIT is a common consequence of antineoplastic regimens for gastrointestinal (GI) cancers, occurring in >60% of colorectal cancer pati...
Impact of HER2 low status on pathologic response after neoadjuvant chemotherapy in TNBC: A large scale retrospective cohort study.
571 Background: HER2 low status, defined as HER2 1+ or HER2 2+ and nonamplified by in-situ hybridization, has demonstrated the ability to identify a popul...
Forecasting incidence and mortality rates of prostate cancer in older adults using autoregressive integrated moving average (ARIMA).
e22574 Background: Prostate cancer is the second most common and fifth deadliest cancer in men worldwide, with incidence and mortality rates influenced by...
The association between recreational physical activity and health-related quality of life among breast cancer survivors: A systematic review.
e23183 Background: Breast cancer survivors are at increased risk of poor health-related quality-of-life (HRQOL). Clinical trials suggest that physical act...
LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
4095 Background: LEAP-002 was a randomized, double-blind, phase 3 study (NCT03713593) that was conducted to evaluate the e...
Prognostic features and clinical panthological factors of acral malignant melanoma.
e21591 Background: Extremity-type malignant melanoma (EMM) can occur at the ends of fingers/toes, under nails, and other extremity sites. This study explo...
Progression-free survival as a surrogate outcome for overall survival in ovarian cancer maintenance therapy randomized controlled trials.
5545 Background: A traditional primary outcome in prospective trials is progression-free survival (PFS). PFS often functions as a surrogate outcome for ov...
Nanoparticle polymeric micellar paclitaxel combined with gemcitabine in first-line treatment of patients with metastatic pancreatic cancer: A single-arm, phase II clinical study.
e16382 Background: Pancreatic cancer remains one of the most lethal malignancies, characterized by limited therapeutic options. This Phase II clinical tri...
A multicenter, pivotal trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) for plasma-based liquid biopsy in patients with glioblastoma (LIBERATE).
TPS2094 Background: Liquid biopsy in glioblastoma (GBM) is hindered by a lack of requisite circulating tumor (ct) and cell-free (cf) DNA levels in blood d...